Tagrisso, a targeted treatment for EGFR mutant non-small cell lung cancer, is not receiving benefits from the first-line treatment in Korea. The medical staff emphasized the need for Tagrisso's benefit.
On the 19th, AstraZeneca Korea held an online press conference to commemorate the 5th anniversary of Tagrisso's postoperative adjuvant therapy acquisition and its launch in Korea. National Cancer Center’s Chief Researcher Ji-Yeon Han and Professor Min-hee Hong, Department of Oncology, Yonsei University Medical School, presented as speakers.

Tagrisso, a third-generation EGFR TKI agent, started as a second-line treatment for EGFR mutant patients and acquired indications for the first-line treatmen